Investing in Transformative Biotech Companies
The Aescap funds invest in publicly traded biotech / life sciences companies. They invest in high-growth, innovative companies that develop and market new medicines and in some cases diagnostics and medical devices. The funds comply with the Dutch Authority Financial Markets (AFM) and are managed by a broad and experienced team with a great track record. A team that has invested a significant amount of money in the Aescap funds themselves. Aescap aims to generate preferred financial returns by choosing a focused investment approach picking around 20 companies per fund. It acts as a private equity player on the stock market by being heavily involved in the companies it invests in. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.
Sustainability
The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today.
We believe everybody has the right to receive the best medical care available. Aescap’s investments have positively affected society and have already resulted in an improvement of the quality of life of millions of people worldwide.
Update via Webcast
Our presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on March 16, 2023 at 15:00 CET.
Meet the Investment Team
The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. Aescap aims to providing a good financial return to their investors, and in parallel contribute to improving the well-being of millions of people. The team invests in the Aescap funds themselves with over 25 million euro.
Biotech Market
The biotech sector, also known as the life sciences sector, is a large and fast-growing sector, driven by an aging population and a high pace of innovation. New medicines like RNA, gene and cell therapies will replace the vast majority of medicine over the coming decades. With around 1000 public biotech companies in the EU and US, it requires sector specific expertise to find de-risked companies with a high earning power that are still undervalued.
Subscribe to our Newsletter here.
Investment Strategy
Find out more about Aescap in this animation.
- Next-generation medicine
- Outstanding management
- High-growth companies
- Diversification within our focus
- Undervalued companies
- Buy and Sell discipline
Latest news
Aescap’s portfolio company Albireo acquired for 84% premium + 44% via CVR
We are reporting to you from the JPMorgan conference in San Francisco where Ipsen and our portfolio company Albireo announced that Ipsen has made an offer to acquire Albireo
Zai Lab’s share price is up 40% after positive phase 3 results in lung cancer
Portfolio company Zai Lab and its partner Novocure announced that the phase 3 study investigating their new therapy for late-stage lung cancer patients resulted in improved overall survival
Biotech Enters New Phase
Biotech companies are rapidly developing new technologies to treat previously incurable diseases.